Literature DB >> 20151608

Propranolol and D-cycloserine as adjunctive medications in reducing dental fear in sedation practice.

Lisa J Heaton1, Daniel W McNeil, Peter Milgrom.   

Abstract

Extensive research and clinical experience have demonstrated the usefulness of sedation in helping fearful patients receive dental treatment, particularly when they have urgent treatment needs. In addition, the efficacy of behavioural programmes for managing dental fears is well established. While often these two approaches are seen as oppositional, our work in Seattle, Morgantown and at King's College London Dental Institute demonstrates the complementarity of the two approaches. Using the example of two compounds, one very familiar, propranolol, and one that has recently become of interest, D-cycloserine, we wish to illustrate the manner in which these medications can be used to enhance behavioural approaches to managing dental anxiety.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151608      PMCID: PMC2893885     

Source DB:  PubMed          Journal:  SAAD Dig        ISSN: 0049-1160


  38 in total

1.  Dental attendance in 1998 and implications for the future.

Authors:  N M Nuttall; G Bradnock; D White; J Morris; J Nunn
Journal:  Br Dent J       Date:  2001-02-24       Impact factor: 1.626

Review 2.  Fear of dental care: are we making any progress?

Authors:  Timothy A Smith; Lisa J Heaton
Journal:  J Am Dent Assoc       Date:  2003-08       Impact factor: 3.634

Review 3.  The amygdala modulates the consolidation of memories of emotionally arousing experiences.

Authors:  James L McGaugh
Journal:  Annu Rev Neurosci       Date:  2004       Impact factor: 12.449

4.  Dental fear in adults: a meta-analysis of behavioral interventions.

Authors:  Gerd Kvale; Ulf Berggren; Peter Milgrom
Journal:  Community Dent Oral Epidemiol       Date:  2004-08       Impact factor: 3.383

5.  Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.

Authors:  Roger K Pitman; Kathy M Sanders; Randall M Zusman; Anna R Healy; Farah Cheema; Natasha B Lasko; Larry Cahill; Scott P Orr
Journal:  Biol Psychiatry       Date:  2002-01-15       Impact factor: 13.382

6.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

7.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

8.  Who is referred for sedation for dentistry and why?

Authors:  C A Boyle; T Newton; P Milgrom
Journal:  Br Dent J       Date:  2009-03-28       Impact factor: 1.626

9.  The association between dental anxiety and oral health-related quality of life in Britain.

Authors:  Colman McGrath; Raman Bedi
Journal:  Community Dent Oral Epidemiol       Date:  2004-02       Impact factor: 3.383

10.  Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction.

Authors:  Jose Rodriguez-Romaguera; Francisco Sotres-Bayon; Devin Mueller; Gregory J Quirk
Journal:  Biol Psychiatry       Date:  2009-02-26       Impact factor: 13.382

View more
  2 in total

1.  Combination Drug Therapy of Pioglitazone and D-cycloserine Attenuates Chronic Orofacial Neuropathic Pain and Anxiety by Improving Mitochondrial Function Following Trigeminal Nerve Injury.

Authors:  Danielle N Lyons; Liping Zhang; Jignesh D Pandya; Robert J Danaher; Fei Ma; Craig S Miller; Patrick G Sullivan; Cristian Sirbu; Karin N Westlund
Journal:  Clin J Pain       Date:  2018-02       Impact factor: 3.442

2.  A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.

Authors:  Maria Urbano; Leonore Okwara; Paul Manser; Kathrin Hartmann; Amy Herndon; Stephen I Deutsch
Journal:  Clin Neuropharmacol       Date:  2014 May-Jun       Impact factor: 1.592

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.